Home » Stocks » Enzo Biochem

Enzo Biochem, Inc. (ENZ)

Stock Price: $2.46 USD -0.04 (-1.60%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 117.81M
Revenue (ttm) 77.42M
Net Income (ttm) -30.58M
Shares Out 47.89M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $2.46
Previous Close $2.50
Change ($) -0.04
Change (%) -1.60%
Day's Open 2.50
Day's Range 2.44 - 2.52
Day's Volume 249,888
52-Week Range 1.56 - 4.85

More Stats

Market Cap 117.81M
Enterprise Value 90.03M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 47.89M
Float 35.44M
EPS (basic) -0.65
EPS (diluted) -0.65
FCF / Share -0.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.29M
Short Ratio 1.22
Short % of Float 5.92%
Beta 0.83
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.52
PB Ratio 1.92
Revenue 77.42M
Operating Income -31.60M
Net Income -30.58M
Free Cash Flow -16.58M
Net Cash 27.78M
Net Cash / Share 0.58
Gross Margin 30.03%
Operating Margin -40.82%
Profit Margin -39.50%
FCF Margin -21.42%
ROA -17.38%
ROE -39.89%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $2.46
Target: 5.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-19.64%-3.88%2.25%5.3%1.72%2.39%-9.1%1.03%5.1%-
Gross Profit23.2540.6345.6145.5842.8341.6838.8747.1148.2144.97
Operating Income1.73-12.16-3.1546.85-1.21-10.18-18.98-40.48-12.93-22.06
Net Income2.49-10.32-2.5045.29-2.29-9.98-18.24-39.27-12.96-22.23
Shares Outstanding47.3546.9746.3546.1545.3642.5639.6138.8038.3638.00
Earnings Per Share0.05-0.22-0.050.97-0.05-0.23-0.46-1.01-0.34-0.59
Operating Cash Flow4.81-2.74-0.2153.13-3.70-1.70-10.02-5.97-8.33-13.46
Capital Expenditures-8.13-1.89-1.75-1.53-1.78-0.84-0.99-1.36-1.22-3.25
Free Cash Flow-3.32-4.62-1.9651.60-5.48-2.54-11.00-7.34-9.55-16.72
Cash & Equivalents60.1560.0464.1767.7818.1117.469.0115.0824.1633.57
Total Debt4.60--1.563.013.013.26---
Net Cash / Debt55.5460.0464.1766.2215.1014.445.7415.0824.1633.57
Book Value86.0381.1288.8789.5542.6136.9534.1349.1088.7297.02
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Enzo Biochem, Inc.
Country United States
Employees 460
CEO Elazar Rabbani

Stock Information

Ticker Symbol ENZ
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NYSE: ENZ


Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in Life Sciences Products, Clinical Laboratory Services, and Therapeutics segments. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 34 patient service centers in New York and New Jersey; and a free standing ?STAT' or rapid response laboratory in New York City and Connecticut, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.